1001415-32-2 Usage
Uses
Used in Pharmaceutical Research and Development:
4-Bromo-1-(phenylsulfonyl)-1H-indazole is used as a building block in organic synthesis for the development of new pharmaceutical compounds. Its unique chemical structure and properties make it a valuable component in the creation of novel therapeutic agents.
Used in Agrochemical Synthesis:
BSI is utilized in the synthesis of various agrochemical products, contributing to the development of new pesticides and other agricultural chemicals that can improve crop protection and yield.
Used in Medicinal Chemistry and Drug Discovery:
4-Bromo-1-(phenylsulfonyl)-1H-indazole is employed as a key intermediate in the design and synthesis of new therapeutic agents for various diseases. Its potential applications in medicinal chemistry make it a promising candidate for the development of innovative treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 1001415-32-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,1,4,1 and 5 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1001415-32:
(9*1)+(8*0)+(7*0)+(6*1)+(5*4)+(4*1)+(3*5)+(2*3)+(1*2)=62
62 % 10 = 2
So 1001415-32-2 is a valid CAS Registry Number.
1001415-32-2Relevant articles and documents
Application of C-H Functionalization in the Development of a Concise and Convergent Route to the Phosphatidylinositol-3-kinase Delta Inhibitor Nemiralisib
Bream, Robert N.,Clark, Hugh,Edney, Dean,Harsanyi, Antal,Hayler, John,Ironmonger, Alan,Mc Cleary, Nadine,Phillips, Natalie,Priestley, Catherine,Roberts, Alastair,Rushworth, Philip,Szeto, Peter,Webb, Michael R.,Wheelhouse, Katherine
, p. 529 - 540 (2021/03/01)
This paper describes the development of an improved and scalable method for the manufacture of nemiralisib, a phosphatidylinositol-3-kinase delta inhibitor. Incorporation of three consecutive catalytic reactions, including a palladium-catalyzed C-H functionalization and an iridium-catalyzed borylation, significantly simplified and shortened the synthetic sequence. The revised route was successfully implemented in a pilot plant on a multikilogram scale to deliver >100 kg of product.
BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES
-
Page/Page column 135, (2009/12/28)
The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.